Sera Prognostics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw the election of two directors for terms expiring in 2029 and the ratification of Ernst & Young as auditors. Shareholders were given opportunities for questions, and management highlighted risks associated with forward-looking statements.
-
Following strong PRIME study results, investments shifted from clinical to commercial focus, extending cash runway through 2029. Key milestones include reimbursement wins, staged provider rollout, and legislative successes like Illinois Medicaid coverage, with broad awareness seen as the main adoption hurdle.
-
Q1 2026 saw continued investment in commercialization and advocacy, with revenue declining to $14,000 and operating expenses stable. Resource realignment is expected to reduce costs by $10 million annually, extending cash runway through 2029.
-
Preterm birth remains a major unmet need, with new trial data showing significant clinical and economic benefits from a bundled intervention. Expansion efforts are focused on Medicaid and commercial payers across more states, with guideline changes and international growth expected in the coming years.
Fiscal Year 2025
-
2025 saw pivotal progress with PRIME study publication, expanded payer and provider engagement, and disciplined financial management. Revenue remains modest, but strong cash reserves and a focused commercial strategy position the company for gradual adoption and growth.
-
Q3 2025 saw continued commercial progress with the first Medicaid pilot live, expanding payer engagement across 13 states, and imminent PRIME study publication. Financials showed stable expenses, a slight net loss improvement, and strong cash reserves.
-
A proteomics-based test for predicting preterm birth was showcased, demonstrating superior efficiency and clinical outcomes compared to traditional methods. Commercialization is underway in targeted states, with strong clinical validation, payer engagement, and digital outreach.
-
Q2 2025 saw continued commercial expansion, strategic leadership hires, and progress toward PRIME Study publication. Revenue declined year-over-year, but operating expenses remained flat and cash reserves are strong, supporting growth initiatives and European market entry.
-
A new lab-developed test for preterm birth prediction, supported by strong clinical data and payer partnerships, is targeting a $3B+ market with rapid Medicaid and commercial adoption. The company is well-funded, scaling operations, and expanding its pipeline in women's health.
-
Q1 2025 saw initial revenue growth and stable losses as commercial expansion began, leveraging PRIME Study results and targeting Medicaid pilots in key states. Updated ACOG guidelines and rising maternal mortality rates support the need for risk-based prenatal care.
-
Preterm birth remains a major health and economic challenge, but a new biomarker test and preventive bundle have shown significant reductions in neonatal morbidity, mortality, and NICU admissions. Strong clinical data, economic benefits, and a robust publication strategy position the innovation for broader adoption and guideline inclusion.
-
A large multi-center trial showed that mid-trimester biomarker screening with targeted interventions significantly reduced neonatal morbidity, NICU admissions, and hospital stays in a low-risk population. The approach outperformed traditional screening and is expected to influence clinical practice and payer priorities.
-
PreTRM, a proteomics-based blood test, predicts preterm birth risk and enables targeted interventions, reducing NICU admissions and hospital stays. Clinical trials demonstrated significant health and economic benefits, supporting payer engagement and US-first commercialization.
Fiscal Year 2024
-
2024 saw pivotal clinical results, a successful capital raise, and strategic commercial expansion, with PRIME study data showing significant reductions in neonatal risks. Cash runway extends through 2028, with 2025 focused on commercialization and evidence-building.
-
A novel blood test for preterm birth risk has shown strong clinical and economic benefits, with pivotal trials supporting its efficacy. Adoption is expected to accelerate as guideline inclusion and payer reimbursement progress, with operational improvements enhancing scalability.
-
Q3 2024 saw continued investment in evidence generation, awareness, and commercial readiness, with revenue down year-over-year and operating expenses up mainly due to stock compensation. PRIME study publication is expected to be a key catalyst for payer and guideline adoption.
-
Preterm birth remains a major health and economic challenge, with a new proteomics-based test showing strong clinical and cost-saving results. The company is driving adoption through targeted state strategies, payer engagement, and broad education, aiming for major growth and regulatory milestones in 2024-2025.
-
Rapid advances in genomic and proteomic testing are transforming maternal and neonatal care, with new studies and improved reimbursement driving broader adoption. Key clinical trials and global initiatives are expected to accelerate mainstream use, while regulatory clarity and updated guidelines will further support growth.
-
Q2 2024 saw key milestones with AVERT study publication and regulatory approval for a new collection method, supporting future growth. Revenue and expenses declined year-over-year, with strong cash reserves and preparations for commercial expansion in 2025.